Gossamer Bio Q4 EPS Forecast Down 26.7% on 19% Revenue Drop
Gossamer Bio is projected to report a 26.7% year-over-year EPS decline to a $0.19 per share loss on 19% lower revenues of $7.6 million for the quarter ended December 2025. Analysts have cut EPS estimates by 1.33% in the past 30 days and maintain a Zacks Rank #2 despite a -30.21% Earnings ESP.
1. Q4 Earnings Expectations
Gossamer Bio is expected to report a loss of $0.19 per share for the quarter ended December 2025, representing a 26.7% decline from the prior year, on revenues forecast at $7.6 million, down 19% year-over-year.
2. Estimate Revisions and Earnings ESP
Analysts have trimmed the consensus EPS estimate by 1.33% over the past 30 days, and the company’s Earnings ESP stands at -30.21%, reflecting recently lowered ‘Most Accurate’ estimates relative to the consensus.
3. Zacks Rank and Historical Surprise Record
The stock carries a Zacks Rank #2 (Buy), but the negative Earnings ESP makes an EPS beat unlikely; historically, Gossamer Bio has beaten estimates three times in the last four quarters despite occasional misses.